Sphere Fluidics

Sphere Fluidics is a Cambridge, UK-based Life Sciences R&D company that specializes in biopharmaceutical discovery and development, cell therapy engineering, bioproduction and synthetic biology, and analysis and isolation. The company is reported to own 25 patented products that include instruments, biochips, and specialist chemicals.[1][2]

Overview

Sphere Fluidics was originally established in 2010, with two chemistry professors of Cambridge University, namely, Professor Chris Abell and Professor Wilhelm Huck, Dr. Frank F. Craig, an entrepreneur, and Dr. Maher Khaled, a Cambridge University Enterprise, as founders.[1][3][4]

Funding

The total funds raised by Sphere Fluidics as of 2017, is reported to be, $13 million through various funding rounds and grants.[3][2][4]

Cyto-Mine Technology

Cyto-Mine is a patented single cell analysis and characterisation system by Sphere Fluidics. This technology is said to aid the development of biotherapeutics for treatment of cancer and inflammatory diseases and vaccine generation. Cyto-Mine is said to be an integrated device which can automatically perform single cell analysis, sorting, imaging and dispensing into individual wells of microtiter plates in a single compact system.[5][6][3]

Awards

2013 : ACES Life Science Award[7][4]

2015: UK's top 50 disruptive SMEs by Real Business[8][9]

2017: European Product Innovation Award[1][10]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.